Respiratory Viruses in Luxembourg (ReViLux)

Weekly report (14 – 20 March 2022)

Executive Summary

The Sentinel Network reported 4.63% of consultations for influenza-like illness, thus exceeding the baseline circulation threshold, according to the European Center for Disease Prevention and Control (ECDC). Within the specimens collected by the Sentinel Network, the influenzavirus A is the most frequently detected virus over the last four weeks (61.7%), followed by SARS-CoV-2 (16.7%) and human rhinovirus (13.3%).

Regarding the SARS-CoV-2 genomic surveillance, the LNS sequenced 657 specimens from residents in Luxembourg in week 11 (of 7779 total cases in the Grand Duchy of Luxembourg; 8.4%). This meets the ECDC recommendations to detect emerging variants. Including PCR screening results, 1485 national specimens were analysed globally (19.1%).

The Omicron variant was the dominant one in the representative sample. The BA.2 lineage remains the most frequent one (85.3%), followed by BA.1 (14.5%). The observed distribution of lineages by age and sex was uneven, and differences were also found by vaccination status, but not by sampling site.



Introduction

The Laboratoire national de santé, as **National Reference Laboratory for Acute Respiratory Infections in Luxembourg**, performs close surveillance on respiratory viruses, with a special focus on SARS-CoV-2. There are currently two active projects:

- **The Sentinel Surveillance Network**. It provides a broad picture of respiratory diseases affecting the Luxembourgish population, based on its double monitoring system (syndromic and virological).
- **The National SARS-COV-2 Genomic Surveillance Program**. It enables detailed observation of SARS-CoV-2 mutations and variants through time and space, and also monitoring specific groups of interest.

The objective of the ReViLux is to inform public health actions in Luxembourg.

Sentinel Surveillance Network

The **Sentinel Surveillance Network** aims at monitoring the circulating respiratory viruses, including SARS-CoV-2, and hence underpin public health actions. Following the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) guidance, it focuses on cases of acute respiratory infection (ARI) and influenza-like illness (ILI).

The current influenza season started in week 40/2021, and the history of ILI consultations is displayed in Figure 1. A detailed summary of the number of ARI and ILI cases during the last four weeks is included in Table 1. In the week of study, 4.63% of consultations were reported as ILI, thus exceeding the threshold for baseline circulation, according to the ECDC (2.59%).

Table 1. Syndromic surveillance over the last 4 weeks.

Week	ARI		ILI		Total consultations
	N	%	N	%	
2022/8	55	18.33	7	2.33	300
2022/9	64	14.55	11	2.50	440
2022/10	81	18.00	24	5.33	450
2022/11	91	21.06	20	4.63	432

ARI: Acute Respiratory Infections; ILI: Influenza-Like Illness.



Figure 1. Percentage of patients with influenza-like illness over the last three seasons

Additionally, a selection of sentinel cases is further studied in order to monitor the circulation of respiratory viruses in the country, as shown in Figure 2. Over the last 4 weeks, influenzavirus A was detected in 61.7% of positive specimens (including 3 co-infection cases), and influenzavirus B in 3.3%. These results are displayed more in detail in Table 2.



Figure 2. Distribution of respiratory viruses detected within the Sentinel Network, by two weeks. Results from last weeks are not yet consolidated.

Co-inf: co-infection; FLU-A: influenzavirus A; FLU-B: influenzavirus B; PIV: parapneumovirus; RSV: respiratory syncytial virus; ADV: adenovirus; MPV: metapneumovirus; HRV: human rhinovirus; SC2: SARS-CoV-2.

Table 2. Distribution of respiratory viruses detected within the Sentinel Network over the last 4 weeks and during the current season.

Virus	Last 4 weeks		Current season	
	N*	%	N*	%
SARS-CoV-2	10	16.7	141	42.5
Human rhinovirus	8	13.3	89	26.8
Influenzavirus A	37	61.7	53	16.0
Metapneumovirus	2	3.3	15	4.5
Respiratory syncytial virus	0	0.0	13	3.9
Parainfluenzavirus	0	0.0	11	3.3
Adenovirus	1	1.7	6	1.8
Influenzavirus B	2	3.3	4	1.2
Total	**60**	**100**	**332**	**100**

**Co-infection cases counted once for each virus detected.*

Laboratoire national de référence pour les infections respiratoires aiguës
Département de microbiologie - Laboratoire national de santé
1, rue Louis Rech | L-3555 Dudelange
T : (+352) 28 100 523 | F : (+352) 28 100 512 | microbiology@lns.etat.lu | www.lns.lu

SARS-CoV-2 Genomic Surveillance

The current sequencing strategy

The National Reference Laboratory for Acute Respiratory Infections at LNS receives SARS-CoV-2 positive samples (nasopharyngeal or oropharyngeal swabs analysed by RT-PCR) from the national network of laboratories and proceeds as follows:

1) Sequencing a representative sample of specimens
2) Sequencing specimens from target groups (i.e. hospital cases and post-vaccination cases)
3) Sequencing specimens from clusters with high transmission.

The representative sample of specimens is a systematic selection from all SARS-CoV-2 positive cases registered in Luxembourg to detect emerging variants and early increases in their incidence and transmission within the community in Luxembourg. This sample is selected according to the ECDC guidelines.

Since the emergence of the Omicron variant of concern, and given the high incidence rates in the European context, targeted PCR tests are carried systematically in order to get an earlier interim evaluation of the variants in circulation. The PCR kits currently used target the following spike mutations: 69/70del, K417N, N501Y.

The LNS shares its sequencing results with GISAID EpiCov database periodically. SARS-CoV-2 lineages have been assigned based on Rambaut et al. using the Phylogenetic Assignment of Named Global Outbreak LINeages (pangolin) software (v3.1.20, pangoLEARN 2022-02-28). The Pango nomenclature is used in addition to the WHO nomenclature to enable easier visualization of links between any evolving variants and their ancestor.

Screening and sequenced specimens



Figure 3. Flowchart of specimens collected during week 11/2022

In week 11, 7779 new cases were registered in Luxembourg; hence, the minimum sample size required to detect emerging variants at a 2.5% incidence is estimated to be 557 specimens (7.2%).

As shown in Figure 3, of all specimens received from the week of study, 1317 were screened by targeted PCR for the Omicron variant (including 1117 national specimens), in order to enable an earlier detection of potential Omicron cases (see results in the following section). In parallel, the microbial genomics unit at the LNS sequenced 751 specimens, including 657 national ones. The weekly sequencing coverage remains at 8.4% (657 out of 7779 cases registered in Luxembourg; see coverage trend in Figure 4), which exceeds the recommended sample size. Overall, 1485 national specimens were analysed either by sequencing or screening (19.1%).



Figure 4. National coverage based on weekly number of positive cases in Luxembourg. The coverage from the latest weeks might not be consolidated yet.

Omicron screening results

As shown in Figure 5, of the 1317 specimens from week 11 screened by targeted PCR, all were identified as potential Omicron cases: 84.5% BA.2 and 15.5% BA.1.



Figure 5. Number of specimens included in the screening for the Omicron variant by date of collection. Results more recent than the week of study are not yet consolidated.

Circulating lineages detection

The distribution of successfully assigned lineages within the national selection is shown in Figure 6. Regarding Delta AY sublineages, only a selection is displayed, based on their prevalence during the last 10 weeks (min. 1%). This distribution is further detailed for the last 2 weeks in Table 4.

The Omicron variant remains the dominant one within the representative sample. The most frequent lineage is now BA.2 (85.3%), followed by BA.1 (14.5%).

A summary of the VOCs assigned among all specimens sequenced (including non-residents) during the last two weeks and since the beginning of the sequencing activity is shown in Table 5.

Table 4. Distribution of SARS-CoV-2 lineages detected within the representative sample during the last two weeks (previously reported cases might be updated by retrospective analysis).

Variant	Previous week			Current week		
	N	%	CI %	N	%	CI %
Omicron	545	100.0	-	556	99.8	99.5 – 100.0
BA.2	426	78.2	74.7 – 81.6	475	85.3	82.3 – 88.2
BA.1	119	21.8	18.4 – 25.3	81	14.5	11.6 – 17.5
BA.1.1	0	-	-	0	-	-
Delta	0	-	-	1	0.2	0.0 – 0.5
Beta	0	-	-	0	-	-
Gamma	0	-	-	0	-	-
Others	0	-	-	0	-	-
Total	**545**	**100.0**	**-**	**557**	**100.0**	**-**



Figure 6. Distribution of lineages within the representative sample during the last 10 weeks.

Table 5. Distribution of VOCs within all samples sequenced (including non-residents)

Variant	**Previous week**		**Current week**		**Cumulative count**
	N	**%**	**N**	**%**	**N**
Delta	1	0.1	1	0.1	12 504
Omicron	785	99.8	685	99.9	10 150
BA.1	162	20.6	101	14.7	7450
BA.2	623	79.2	584	85.1	2696
BA.1.1	0	-	0	-	4
Gamma	0	-	0	-	1305
Beta	0	-	0	-	1255
Other	0	-	0	-	12 171
Total	**786**	**100.0**	**686**	**100.0**	**37 385**

Clinical and epidemiological factors

In this section, the lineage distribution of all specimens sequenced is assessed by demographics (sex and age group, Figure 7), sampling setting (community vs. hospital, Table 6) and vaccination status (not vaccinated vs. fully vaccinated, Table 7).



Figure 7. Age group and sex distribution of specimens sequenced over the last 3 weeks, by lineage. F

Table 6. Comparison of lineage distribution by sampling setting.

Lineage	Community			Hospital		
	Women	Men	Total	Women	Men	Total
Omicron BA.2	78.1%	78.9%	78.5%	78.3%	78.0%	78.2%
Omicron BA.1	21.9%	21.1%	21.5%	21.7%	22.0%	21.8%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Table 7. Comparison of lineage distribution by vaccination status.

Lineage	Not vaccinated			Fully vaccinated		
	Women	Men	Total	Women	Men	Total
Omicron BA.2	83.8%	83.3%	83.6%	77.4%	74.1%	76.0%
Omicron BA.1	16.2%	16.7%	16.4%	22.6%	25.9%	24.0%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Mutation surveillance

In addition to the surveillance of SARS-CoV-2 variants, the LNS monitors the occurrence of SARS-CoV-2 mutations reported to have a clinical and epidemiological relevance. This complementary surveillance enables us to detect unexpected mutations among the specimens sequenced. Newly acquired mutations may occur and their early detection might be key to expect changes in the epidemic evolution. Following ECDC guidance, the LNS is currently monitoring 42 mutations to the spike protein frequently associated to VOCs. As each VOC is characterised by a set of defining mutations, which are expected to be highly present, it is interesting to analyse the non-defining ones. Among the specimens collected over the last four weeks, the following mutations were detected (minimum 1% prevalence):

- BA.1 specimens:
    - A701V (in at least 2.6%), frequently associated to the Beta variant.

Concerning BA.1 specimens, the A701V mutation continues to show a decreasing trend and remains below the rate in the European region (according to GISAID). Concerning BA.2 specimens, no mutations were detected in at least 1% specimens.

References

Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Retrieved 28 March 2022, from https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html

COVID-19 Data Portal - accelerating scientific research through data. (2021). Retrieved 28 March 2022, from https://www.covid19dataportal.org/sequences

Direção-Geral da Saúde. Relatório de Situação. Retrieved 28 March 2022, from https://covid19.min-saude.pt/relatorio-de-situacao/

European Centre for Disease Prevention and Control. Guidance for representative and targeted genomic SARS-CoV-2 monitoring – 3 May 2021. ECDC : Stockholm ; 2021

European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern. Retrieved 28 March 2022, from https://www.ecdc.europa.eu/en/covid-19/variants-concern

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health. Geneva: World Health Organization; 2021.

GISAID. EpiCoV – Pandemic coronavirus causing COVID-19. Retrieved 28 mars 2022, from https://www.gisaid.org

GitHub - cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. (2021). Retrieved 28 March 2022, from https://github.com/cov-lineages/pangolin

Hadfield J., Megill C., Bell S., Huddleston J., Potter B., Callender C. et al. (2018). Nextstrain: real-time tracking of pathogen evolution. Bioinformatics, 34(23), 4121-4123. doi: 10.1093/bioinformatics/bty407

Instituto Nacional de Saúde Doutor Ricardo Jorge. Diversidade genética do novo coronavírus SARS-CoV-2 (COVID-19) em Portugal. Retrieved 28 March 2022, from https://insaflu.insa.pt/covid19/

Pango Network. New AY lineages. Retrieved 28 March 2022, from: https://www.pango.network/new-ay-lineages-and-an-update-to-ay-4-ay-12/

Rambaut A., Holmes E., O'Toole Á., Hill V., McCrone J., Ruis C. et al. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology, 5(11), 1403-1407. doi: 10.1038/s41564-020-0770-5

Robert Koch Institut. Aktueller Lage-/Situationsbericht des RKI zu COVID-19. Retrieved 28 March 2022, from https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html;jsessionid=69BC18053F9591C56EB148E463103DB7.internet101

Santé publique France. Coronavirus : chiffres clés et évolution de la COVID-19 en France et dans le Monde. Retrieved 28 March 2022, from https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde

Santé publique France. Enquêtes Flash : évaluation de la circulation des variants du SARS-CoV-2 en France. Retrieved 28 March 2022, from https://www.santepubliquefrance.fr/etudes-et-enquetes/enquetes-flash-evaluation-de-la-circulation-des-variants-du-sars-cov-2-en-france

Sciensano. COVID-19 – Bulletin épidémiologique hebdomadaire. Retrieved 28 March 2022, from https://covid-19.sciensano.be/fr/covid-19-situation-epidemiologique

The Luxembourgish data platform. COVID-19: Rapports hebdomadaires. Retrieved 28 March 2022, from https://data.public.lu/en/datasets/covid-19-rapports-hebdomadaires/

Laboratoire national de référence pour les infections respiratoires aiguës
Département de microbiologie - **Laboratoire national de santé**
1, rue Louis Rech | L-3555 Dudelange
T : (+352) 28 100 523 | F : (+352) 28 100 512 | microbiology@lns.etat.lu | www.lns.lu